Literature DB >> 16498502

The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.

Farnaz D Fakhari1, Joseph H Jeong, Yogita Kanan, Dirk P Dittmer.   

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV) is a human lymphotropic herpesvirus. It is implicated in B cell neoplasias such as primary effusion lymphoma and multicentric Castleman disease in AIDS patients. The KSHV latency-associated nuclear antigen (LANA) is consistently expressed in all KSHV-associated tumor cells and was shown to bind the tumor suppressor proteins p53 and pRb. To test LANA's contribution to lymphomagenesis in vivo we generated transgenic mice expressing LANA under the control of its own promoter, which is B cell specific. All of the transgenic mice developed splenic follicular hyperplasia due to an expansion of IgM+ IgD+ B cells and showed increased germinal center formation. We also observed lymphomas, implying that LANA can activate B cells and provide the first step toward lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498502      PMCID: PMC1378187          DOI: 10.1172/JCI26190

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells.

Authors:  Jill T Bechtel; Yuying Liang; Joshua Hvidding; Don Ganem
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays.

Authors:  Dirk P Dittmer
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

3.  Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis.

Authors:  Adam Grundhoff; Don Ganem
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

4.  Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes.

Authors:  Silvia Montaner; Akrit Sodhi; Alfredo Molinolo; Thomas H Bugge; Earl T Sawai; Yunsheng He; Yi Li; Patricio E Ray; J Silvio Gutkind
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

5.  Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts.

Authors:  Ulf Klein; Annunziata Gloghini; Gianluca Gaidano; Amy Chadburn; Ethel Cesarman; Riccardo Dalla-Favera; Antonino Carbone
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

6.  The tumor microenvironment controls primary effusion lymphoma growth in vivo.

Authors:  Michelle R Staudt; Yogita Kanan; Joseph H Jeong; James F Papin; Rebecca Hines-Boykin; Dirk P Dittmer
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

7.  Tissue specificity of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen (LANA/orf73) promoter in transgenic mice.

Authors:  Joseph H Jeong; Rebecca Hines-Boykin; John D Ash; Dirk P Dittmer
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile.

Authors:  Richard G Jenner; Karine Maillard; Nicola Cattini; Robin A Weiss; Chris Boshoff; Richard Wooster; Paul Kellam
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

9.  The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis.

Authors:  Emmy W Verschuren; J Graeme Hodgson; Joe W Gray; Scott Kogan; Nic Jones; Gerard I Evan
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

10.  Risk of malignant lymphoma associated with human herpesvirus-8: a case-control study in Spain.

Authors:  S de Sanjosé; J J Goedert; V Marshall; C Bellas; Y Benavente; R Bosch; A Domingo; A Fernandez de Sevilla; O Servitje; D Whitby
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

View more
  57 in total

Review 1.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

2.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 3.  Kaposi's sarcoma and its associated herpesvirus.

Authors:  Enrique A Mesri; Ethel Cesarman; Chris Boshoff
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

4.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes.

Authors:  Jianxin You; Viswanathan Srinivasan; Gerald V Denis; William J Harrington; Mary E Ballestas; Kenneth M Kaye; Peter M Howley
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 5.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

6.  KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice.

Authors:  Christopher H Parsons; Laura A Adang; Jon Overdevest; Christine M O'Connor; J Robert Taylor; David Camerini; Dean H Kedes
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

7.  Determination of Kaposi's sarcoma-associated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding.

Authors:  Brenna Kelley-Clarke; Mary E Ballestas; Viswanathan Srinivasan; Andrew J Barbera; Takashi Komatsu; Te-Ana Harris; Mia Kazanjian; Kenneth M Kaye
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

Review 8.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

9.  mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.

Authors:  Debasmita Roy; Sang-Hoon Sin; Amy Lucas; Raman Venkataramanan; Ling Wang; Anthony Eason; Veenadhari Chavakula; Isaac B Hilton; Kristen M Tamburro; Blossom Damania; Dirk P Dittmer
Journal:  Cancer Res       Date:  2013-02-04       Impact factor: 12.701

10.  Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation.

Authors:  Sang-Hoon Sin; Sun Ah Kang; Yongbaek Kim; Anthony Eason; Kelly Tan; Hyowon An; Dirk P Dittmer
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.